Integrated bioinformatics analysis to explore potential therapeutic targets and drugs for small cell carcinoma of the esophagus by Maofei Zhu, Maofei Zhu, Yueming Chu, Yueming Chu, Qiang Yuan, Qiang Yuan, Junfeng Li, Silin Chen, Lin Li, Lin Li, Lin Li

“…Crizotinib, lapatinib, and rucaparib can act on the above targets to inhibit the progression of SCCE and play a therapeutic role.…”
Get full text

PARP Inhibitors in the Treatment of Ovarian Cancer by Andrzej Paweł Zuzak, Magdalena Cieślik-Porębska, Krzysztof Kułak, Jagoda Niewiadomska

“…Olaparib, niraparib, and rucaparib have become integral to ovarian cancer management, offering effective options for patients with BRCA mutations or homologous recombination deficiencies. …”
Get full text

Poly-ADP ribose polymerase (PARP) inhibitor regimens for platinum-sensitive ovarian cancer in randomized, double-blind, phase III controlled trials: protocol for a systematic revie... by Xiaolian Peng, Jie Liu

“…To evaluate and compare the efficacy and side effects of various PARP inhibitors.MethodsWe plan to conduct a network meta-analysis that includes randomized, double-blind, controlled phase III trials of Niraparib, Rucaparib, Olaparib, or Veliparib in patients with Platinum-sensitive ovarian cancer. …”
Get full text

PARP‐1 Inhibition Increases Oxidative Stress in Ets‐1‐Expressing MDA‐MB‐231 Breast Cancer Cells by Magalie Hervieu, Arnaud J. Legrand, Emilie Floquet, Thierry Idziorek, Corentin Spriet, Didier Monté, Vincent Villeret, Marc Aumercier, Souhaila Choul‐li

“…Methods and Results We tested the effects of four PARP inhibitors (PARPi) (PJ‐34, Veliparib, Olaparib, and Rucaparib). We first demonstrated that PARPi reduced cells growth through G2/M cell cycle arrest. …”
Get full text

A comprehensive comparison of PARP inhibitors as maintenance therapy in platinum-sensitive recurrent ovarian cancer: a systematic review and network meta-analysis by Shiya Ji, Lu Chen, Yebo Yu, Xupeng Chen, Liwen Wei, Lili Gou, Cheng Shi, Susu Zhuang

“…Results Six randomized controlled trials were examined and the four PARPis (olaparib, niraparib, rucaparib and fuluzolparib) have been found to significantly increase the PFS in entire population as well as in subgroups of HRD and BRCAm (BRCA mutation). …”
Get full text

Incidence and risk of endocrine and metabolic abnormalities linked to PARP inhibitors in solid tumors: a meta-analysis by Shunlian Fu, Pingjin Zou, Zengyi Fang, Xinxiang Zhou, Junyang Chen, Cuicui Gong, Li Quan, Bing Lin, Qiu Chen, Jinyi Lang, Meihua Chen

“…Niraparib demonstrated an increased risk of any-grade hyperglycemia (OR = 2.15, 95% CI 1.28–3.62), with patients receiving PARPi for metastatic pancreatic cancer showing a higher susceptibility to any-grade hyperglycemia (OR = 1.78, 95% CI 1.04–3.04). Conversely, rucaparib exhibited a potential ameliorative effect on hyperglycemia (OR = 0.54, 95% CI 0.30–0.97). …”
Get full text